Phase 2 Endometrial Cancer Trial, Recruiting NCT03617133 Sponsor: Medical University of Vienna Condition: Endometrial Cancer
Back to Endometrial Cancer

Phase 2 Endometrial Cancer Trial, Recruiting

NCT03617133
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have cervical cancer that doctors believe can be treated with the goal of a cure, using radiation therapy (with or without chemotherapy) and a type of internal radiation called brachytherapy (BT)
  • A biopsy has confirmed your cervical cancer is one of these types: squamous-cell carcinoma, adenocarcinoma, or adeno-squamous cell carcinoma
  • Your cancer has been formally staged (measured and classified) using standard medical guidelines
  • You have had an MRI scan of your pelvis at the time of diagnosis
  • You have had an MRI, CT, or PET-CT scan of your abdomen and the area around your spine at the time of diagnosis
  • You are able to have an MRI scan done while the brachytherapy applicator (a small device used to deliver internal radiation) is in place
  • You may still be eligible if cancer has spread to certain lymph nodes in the lower part of the abdomen (below a specific spinal level called L1-L2)
  • You are able and willing to give your informed consent to take part

Who may not be able to join:

  • You have another active cancer, other than a very early-stage cervical abnormality or a common type of non-spreading skin cancer (basal cell carcinoma)
  • Your cervical cancer is a rare type, such as small cell neuroendocrine cancer, melanoma, or other uncommon cervical cancers
  • Your cancer has spread to areas beyond the lower abdominal lymph node region (above the L1-L2 spinal level)
  • You have previously had radiation therapy to your pelvis or abdomen
  • You have previously had surgery to remove all or part of your uterus (hysterectomy)
  • Your treatment plan combines radiation given before surgery with an operation
  • You are only receiving internal radiation (brachytherapy) without external radiation
  • You are only receiving external radiation without internal radiation (brachytherapy)
  • You are receiving chemotherapy before the main treatment, or any cancer treatment other than a specific weekly chemotherapy drug called cisplatin — although a specific course of chemotherapy after the main treatment (carboplatin and paclitaxel) may be allowed depending on your hospital's policy (confirm with trial site)
  • You have a medical reason why you cannot have an MRI scan
  • You have a medical reason why you cannot have brachytherapy (internal radiation)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Richard Pötter, MD, Medical University of Vienna

Phone: 0043140400

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
1 April 2016
Est. completion
31 December 2021

Where this trial is recruiting

🇦🇹 Austria

Primary endpoints

local control; nodal control; systemic control; overall survival; overall morbidity; health-related quality of life: physical functioning; health-related quality of life: role functioning; health-related quality of life: social functioning

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov